BRCA1/2 Mutation Genetic Screening and Hereditary Cancer Treatment (Review Article)

Author(s): E.Priya*

Abstract: The new Genomics topic area and objectives for 2020 reflect the increasing scientific evidence supporting the health benefits of using genetic tests and family health history to guide clinical and public health interventions. Women with certain high-risk family health history patterns for breast and ovarian cancer could benefit from receiving genetic counselling to learn about genetic testing for BRCA1/2. About 5% to 10% of Pancreatic cancers are caused by germ-line mutations in BRCA1, BRCA2 or PALB2 genes, and this subset of tumors may demonstrate significant sensitivity to DNA damaging agents and PARP1 inhibitors. Multiple lines of evidence indicate that BRCA1-related cancers may derive less benefit from taxane-based treatment than other categories of cancer patients. Ongoing revolution in technologies of DNA analysis, particularly the invention of next-generation sequencing, allows expecting that dozens of new familial cancer genes will be identified in the near future. This article brings you the concept of mutation responsible for breast cancer, hereditary risk factors, genetic features of BRCA genes, methods for diagnosis, treatment procedures and different prevention methodologies.

PAGES: 01-06  |  141 VIEWS  195 DOWNLOADS